中医药防治非酒精性脂肪性肝病的作用机制研究进展

王亚楠; 张金朋; 夏美卉; 任谦谊; 韩信慧; 梁国英

doi:10.16766/j.cnki.issn.1674-4152.004381

中医药防治非酒精性脂肪性肝病的作用机制研究进展

doi: 10.16766/j.cnki.issn.1674-4152.004381

王亚楠^{1, 2},
张金朋^{1, 2},
夏美卉^{1, 3},
任谦谊¹,
韩信慧¹,
梁国英^{1, 4, ,}

1.
黑龙江中医药大学研究生院，黑龙江哈尔滨 150040
2.
黑龙江中医药大学附属第二医院康复科，黑龙江哈尔滨 150001
3.
黑龙江中医药大学附属第二医院内分泌科
4.
黑龙江中医药大学附属第一医院消化科，黑龙江哈尔滨 150040

基金项目:

黑龙江省科研中医药科研项目 ZHY2024-185

详细信息

通讯作者:
梁国英，E-mail：1078720583@qq.com

中图分类号: R256.4 R575.5
计量
- 文章访问数: 7
- HTML全文浏览量: 3
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2025-04-30
- 网络出版日期: 2026-04-11

Research progress on the mechanism of traditional Chinese medicine in the prevention and treatment of non-alcoholic fatty liver disease

WANG Yanan^{1, 2},
ZHANG Jinpeng^{1, 2},
XIA Meihui^{1, 3},
REN Qianyi¹,
HAN Xinhui¹,
LIANG Guoying^{1, 4
, ,}

1.
Graduate School of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China

摘要

摘要: 目前非酒精性脂肪性肝病(NAFLD)发病率越来越高，已成为全球性的健康问题。NAFLD主要表现为肝细胞内脂肪的异常堆积，是一种代谢性疾病，病理机制复杂，与胰岛素抵抗、内质网应激、线粒体功能障碍、氧化应激、自噬、肠道菌群异常等密切相关。目前，西医在NAFLD的治疗上尚未找到特效药物，而中医药在NAFLD防治领域展现出独特优势和巨大潜力。中医认为其病机核心在于肝失疏泄、脾失健运，导致痰湿与瘀血相互交织，阻滞肝络，使体内肥浊之气积聚于肝脏。治疗上以疏肝健脾、化浊祛瘀为基本原则。近年来，大量研究聚焦于中药复方、单药及活性成分的作用机制，揭示其通过多靶点、多通路协同调节有效干预NAFLD进程的核心途径，然而，关于中医药防治NAFLD作用机制的全面综述文章相对较少。本综述系统整合了中医药防治NAFLD的最新研究成果，深入剖析了其基于整体观和辨证论治原则，在分子、细胞及系统层面的多层次、多靶点作用机制。这不仅为深入理解NAFLD的复杂发病网络提供了独特视角，也为临床精准应用中医药、开发基于中药的创新疗法提供了坚实的理论基础和重要的研究方向。
- 非酒精性脂肪性肝病 /
- 中医药 /
- 病理机制 /
- 作用机制 /
- 研究进展
Abstract: The incidence of Non-alcoholic fatty liver disease (NAFLD) has increased markedly and it has become a global health issue. NAFLD is characterized by an abnormal accumulation of fat in hepatocytes and is a metabolic disorder with a complex pathological mechanism closely related to insulin resistance, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress, autophagy and abnormal gut microbiota. At present, Western medicine has not identified a specific pharmaceutical treatment for NAFLD, whereas traditional Chinese medicine (TCM) has demonstrated unique advantages and significant potential in the prevention and treatment of NAFLD. According to TCM, the fundamental cause of the disease lies in the liver' s inability to maintain adequate dispersion and dredging function and the spleen' s incapacity to carry out its normal transportation and transformation processes. This results in the complex interplay of phlegm-dampness and blood stasis, which impede the liver collaterals, leading to causing the accumulation of turbid and fatty qi within the liver. With regard to the treatment of this condition, the fundamental principles are to soothe the liver and strengthen the spleen, as well as to resolve turbidity and remove stasis. In recent years, a significant number of studies have concentrated on the mechanism of action of TCM compound prescriptions, single herbs and active ingredients, revealing the core pathways through which they effectively intervene in the progression of NAFLD through multi-target and multi-pathway coordinated regulation. However, there is a paucity of comprehensive review articles on the mechanism of TCM in the prevention and treatment of NAFLD. This review systematically integrates the latest research results of TCM in the prevention and treatment of NAFLD, and carries out a profound analysis of its multi-level and multi-target action mechanisms at the molecular, cellular, and system levels based on a holistic view and the principle of syndrome differentiation and treatment. This provides a unique perspective for a deeper understanding of the complex pathogenesis network of NAFLD, as well as provides a solid theoretical basis and important research direction for the precise clinical application of TCM and the development of innovative therapies based on traditional Chinese medicine.
- Non-alcoholic fatty liver disease /
- Traditional Chinese medicine /
- Pathological mechanism /
- Mechanism of action /
- Research progress

HTML全文

参考文献(50)

[1]	STEFAN N, CUSI K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes[J]. Lancet Diabetes Endocrinol, 2022, 10(4): 284-296. doi: 10.1016/S2213-8587(22)00003-1
[2]	TARGHER G, TILG H, BYRNE C D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 578-588. doi: 10.1016/S2468-1253(21)00020-0
[3]	NEUSCHWANDER-TETRI B A. Therapeutic landscape for NAFLD in 2020[J]. Gastroenterology, 2020, 158(7): 1984-1998. e3. doi: 10.1053/j.gastro.2020.01.051
[4]	黄超原, 赵志敏, 李炜, 等. 中医药通过PPAR相关通路干预非酒精性脂肪肝的实验研究[J]. 中国中医基础医学杂志, 2023, 29(12): 2112-2116. HUANG C Y, ZHAO Z M, LI W, et al. Experimental study on traditional chinese medicine intervening in non-alcoholic fatty liver disease through PPAR-related pathways[J]. Journal of Basic Chinese Medicine, 2023, 29(12): 2112-2116.
[5]	苏志威, 薛娟, 孙俊, 等. 中医药调控TLR4信号通路干预非酒精性脂肪肝的实验研究进展[J]. 中国实验方剂学杂志, 2025, 31(5): 291-299. SU Z W, XUE J, SUN J, et al. Research progress on experimental studies of traditional chinese medicine regulating TLR4 signaling pathway to intervene in non-alcoholic fatty liver disease[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2025, 31(5): 291-299.
[6]	杨慧茹, 黄昶煜东, 朱丽英, 等. 基于网络药理学方法和动物实验探讨制何首乌治疗非酒精性脂肪肝病的作用机制[J]. 世界科学技术-中医药现代化, 2023, 25(11): 3678-3691. YANG H R, HUANG C Y D, ZHU L Y, et al. Exploring the mechanism of processed polygonum multiflorum in treating non-alcoholic fatty liver disease based on network pharmacology and animal experiments[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2023, 25(11): 3678-3691.
[7]	赵传志, 丁慧敏, 胡紫晴, 等. 苓桂术甘汤干预非酒精性脂肪肝病的药效学研究及作用机制探讨[J]. 海南医学院学报, 2024, 30(1): 29-38. ZHAO C Z, DING H M, HU Z Q, et al. Pharmacodynamic study and mechanism of action of Linggui Zhugan Decoction in the intervention of nonalcoholic fatty liver disease[J]. Journal of Hainan Medical University, 2024, 30(1): 29-38.
[8]	邹嘉曦, 冯全生. 冯全生从湿浊论治非酒精性脂肪肝经验[J]. 中华中医药杂志, 2021, 36(3): 1472-1474. ZOU J X, FENG Q S. Feng Quansheng' s experience in treating non-alcoholic fatty liver disease from the perspective of "Shizhuo"[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2021, 36(3): 1472-1474.
[9]	李柏, 金妍, 王栋先, 等. 应用血浊"理论治疗代谢性疾病研究进展[J]. 山东中医杂志, 2024, 43(3): 322-327. LI B, JIN Y, WANG D X, et al. Research progress on the treatment of metabolic diseases by applying the ""Xuezhuo"" theory[J]. Shandong Journal of Traditional Chinese Medicine, 2024, 43(3): 322-327.
[10]	段旭冰, 陈文慧, 王仕奇, 等. 非酒精性脂肪性肝病伏邪"痰浊脂膏"与脂稳态关系探究[J]. 中华中医药杂志, 2021, 36(12): 7099-7102. DUAN X B, CHEN W H, WANG S Q, et al. Exploration on the relationship between latent pathogen ""Tanzhuozhigao"" and lipid homeostasis in non-alcoholic fatty liver disease[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2021, 36(12): 7099-7102.
[11]	白敏, 黄烈平, 朱蓓, 等. 瘦素水平在肥胖儿童胰岛素抵抗与非酒精性脂肪肝间的中介效应[J]. 中华全科医学, 2023, 21(12): 2086-2088, 2105. BAI M, HUANG L P, ZHU B, et al. Mediating effect of leptin level between insulin resistance and non-alcoholic fatty liver disease in obese children[J]. Chinese Journal of General Practice, 2023, 21(12): 2086-2088, 2105.
[12]	QIAN H, CHAO X, WILLIAMS J, et al. Autophagy in liver diseases: a review[J]. Mol Aspects Med, 2021, 82: 100973. DOI: 10.1016/j.mam.2021.100973.
[13]	REN Q, SUN Q, FU J. Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease[J]. Autophagy, 2024, 20(2): 221-241. doi: 10.1080/15548627.2023.2254191
[14]	雷森林, 李先辉, 伍方佳. 脂噬在非酒精性脂肪性肝病中的作用及运动调节机制的研究进展[J]. 中国病理生理杂志, 2025, 41(1): 165-172. LEI S L, LI X H, WU F J. Research progress on the role of lipophagy in non-alcoholic fatty liver disease and its regulatory mechanism by exercise[J]. Chinese Journal of Pathophysiology, 2025, 41(1): 165-172.
[15]	TILG H, ADOLPH T E, TRAUNER M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34(11): 1700-1718. doi: 10.1016/j.cmet.2022.09.017
[16]	REBELOS E, IOZZO P, GUZZARDI M A, et al. Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease[J]. World J Gastroenterol, 2021, 27(30): 4999-5018. doi: 10.3748/wjg.v27.i30.4999
[17]	WANG X X, ZHANG B, XIA R, et al. Inflammation, apoptosis and autophagy as critical players in vascular dementia[J]. Eur Rev Med Pharmacol Sci, 2020, 24(18): 9601-9614.
[18]	WANG Y Z, ZHENG J M, HOU H T, et al. Effects of berberine on intestinal flora of non-alcoholic fatty liver induced by high-fat diet through 16S rRNA gene seg-mentation[J]. J King Saud Univ Sci, 2020, 32(5): 2603-2609. doi: 10.1016/j.jksus.2020.04.020
[19]	NASSER M I, ZHU S, CHEN C, et al. A comprehensive review on schisandrin B and its biological properties[J]. Oxid Med Cell Longev, 2020(1): 2172740. DOI: 10.1155/2020/2172740.
[20]	颜丽珊, 康建英, 顾春宇, 等. 五味子乙素通过调控mTOR/TFEB通路抑制非酒精性脂肪性肝病细胞模型脂质堆积作用及机制研究[J]. 辽宁中医药大学学报, 2025, 27(6): 26-31. YAN L S, KANG J Y, GU C Y, et al. Study on the effect and mechanism of schisandrin b in inhibiting lipid accumulation in non-alcoholic fatty liver disease cell model by regulating mTOR/TFEB pathway[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2025, 27(6): 26-31.
[21]	朱智峰, 李文婷, 曹拥军, 等. 基于生物信息学探讨五味子乙素抑制铁死亡改善蛋氨酸胆碱缺乏诱导脂肪肝模型小鼠的作用机制[J]. 中国实验方剂学杂志, 2025, 31(2): 74-83. ZHU Z F, LI W T, CAO Y J, et al. Exploring the mechanism of schisandrin B in inhibiting ferroptosis and improving methionine-choline deficiency-induced fatty liver model mice based on bioinformatics[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2025, 31(2): 74-83.
[22]	PEI L, HE L. Hepatoprotective effect of anemoside B4 against sepsis-induced acute liver injury through modulating the mTOR/p70S6K-mediated autophagy[J]. ChemBiol Interact, 2021, 345: 109534. DOI: 10.1016/j.cbi.2021.109534.
[23]	谢蓉, 张民权, 李莹, 等. 大黄素药理作用及新剂型研究进展[J]. 中华中医药学刊, 2023, 41(12): 120-125. XIE R, ZHANG M Q, LI Y, et al. Research progress on pharmacological effects and new dosage forms of emodin[J]. Chinese Archives of Traditional Chinese Medicine, 2023, 41(12): 120-125.
[24]	杨宗慧, 陈红刚, 赵文龙, 等. 大黄及有效成分治疗脂肪肝作用机制的研究进展[J]. 中药药理与临床, 2025, 41(7): 113-120. YANG Z H, CHEN H G, ZHAO W L, et al. Research progress on mechanism of Dahuang and its active components in the treatment of fatty liver[J]. Pharmacology and Clinics of Chinese Materia Medica, 2025, 41(7): 113-120.
[25]	刘家骥, 时志鹏, 杨强, 等. 大黄素治疗代谢相关脂肪性肝病的作用机制研究进展[J]. 现代药物与临床, 2022, 37(8): 1898-1902. LIU J J, SHI Z P, YANG Q, et al. Research progress on mechanism of emodin in treatment of metabolic associated fatty liver disease[J]. Drugs & Clinic, 2022, 37(8): 1898-1902.
[26]	余琳媛, 龚莉虹, 汤韵秋, 等. 基于AMPK信号通路的大黄素治疗非酒精性脂肪肝病研究进展[J]. 中国实验方剂学杂志, 2020, 26(2): 203-209. YU L Y, GONG L H, TANG Y Q, et al. Research progress on emodin in the treatment of non-alcoholic fatty liver disease based on AMPK signaling pathway[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020, 26(2): 203-209.
[27]	何基泽, 龙小琴, 聂聪, 等. 铁皮石斛BBS基因家族生物信息学及表达分析[J]. 基因组学与应用生物学, 2022, 41(6): 1329-1338. HE J Z, LONG X Q, NIE C, et al. Bioinformatics and expression analysis of BBS gene family in dendrobium officinale[J]. Genomics and Applied Biology, 2022, 41(6): 1329-1338.
[28]	洪静, 杨方瑶, 蒋立翔, 等. 天然产物活性分子毛兰素抗肿瘤作用研究进展[J]. 生物学杂志, 2022, 39(6): 89-93. HONG J, YANG F Y, JIANG L X, et al. Research progress on antitumor effect of erianin, an active molecule from natural products[J]. Journal of Biology, 2022, 39(6): 89-93.
[29]	窦博. 毛兰素抗溃疡性结肠炎活性的研究[D]. 长春: 吉林大学, 2020. DOU B. Study on the anti-ulcerative colitis activity of erianin[D]. Jilin: Jilin University, 2020.
[30]	李洪睿, 周子艺, 侯宇轩, 等. 毛兰素对非酒精性脂肪肝小鼠的改善作用及相关机制探讨[J]. 中药材, 2024, 47(11): 2876-2879. LI H R, ZHOU Z Y, HOU Y X, et al. Improvement effect of erianin on mice with non-alcoholic fatty liver disease and exploration of its related mechanisms[J]. Journal of Chinese Medicinal Materials, 2024, 47(11): 2876-2879.
[31]	高满军, 赵宝清, 莫启贵, 等. 茯苓的化学成分及其调节糖脂代谢的研究进展[J]. 湖北科技学院学报(医学版), 2023, 37(3): 272-276. GAO M J, ZHAO B Q, MO Q G, et al. Research progress on chemical constituents of poria cocos and its regulation of glucose and lipid metabolism[J]. Journal of Hubei University of Science and Technology(Medical Sciences), 2023, 37(3): 272-276.
[32]	YE H, MA S, QIU Z, et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis[J]. J Ethnopharmacol, 2022, 296: 115457. DOI: 10.1016/j.jep.2022.115457.
[33]	TAN Y Y, YUE S R, LU A P, et al. The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis[J]. Phytomedicine, 2022, 103: 154208. DOI: 10.1016/j.phymed.2022.154208.
[34]	王琪格, 曹媛, 宋囡, 等. 茯苓多糖对ApoE^-/-AS小鼠肝脏脂质沉积及胆固醇逆向转运相关蛋白表达的影响[J]. 世界科学技术-中医药现代化, 2022, 24(7): 2637-2643. WANG Q G, CAO Y, SONG N, et al. Effect of poria polysaccharide on hepatic lipid deposition and expression of cholesterol reverse transport-related proteins in ApoE-/-AS mice[J]. World Science and Technology-Modernization of Traditional Chinese Medicine, 2022, 24(7): 2637-2643.
[35]	姜悦航, 张越, 王妍妍, 等. 茯苓多糖提取物调控CYP2E1及NF-κB炎症通路改善小鼠酒精性肝病[J]. 中国中药杂志, 2022, 47(1): 134-140. JIANG Y H, ZHANG Y, WANG Y Y, et al. Poria polysaccharide extract improves alcoholic liver disease in mice by regulating CYP2E1 and NF-κB inflammatory pathway[J]. China Journal of Chinese Materia Medica, 2022, 47(1): 134-140.
[36]	黄诗瑶, 孔亮, 王佳华, 等. 茯苓多糖通过调控Akt/mTOR/SREBP-1c信号通路对非酒精性脂肪性肝病小鼠的改善作用[J]. 中成药, 2025, 47(1): 58-65. HUANG S Y, KONG L, WANG J H, et al. Improvement effect of poria polysaccharide on mice with non-alcoholic fatty liver disease by regulating Akt/mTOR/SREBP-1c signaling pathway[J]. Chinese Traditional Patent Medicine, 2025, 47(1): 58-65.
[37]	王敏, 周璐, 孙燕, 等. 大柴胡汤及其"方剂要素"对NAFLD模型大鼠"肠-肝轴"作用的相关分析[J]. 世界中医药, 2021, 16(3): 430-436. WANG M, ZHOU L, SUN Y, et al. Correlative analysis of dachaihu decoction and its ""formula elements"" on the ""gut-liver axis"" in NAFLD model rats[J]. World Chinese Medicine, 2021, 16(3): 430-436.
[38]	钟光成, 刘启华, 麦灏铭, 等. 基于网络药理学及实验验证探讨大柴胡汤抗非酒精性脂肪性肝病的作用机制[J]. 中药药理与临床, 2025, 41(3): 2-9. ZHONG G C, LIU Q H, MAI H M, et al. Exploring the mechanism of dachaihu decoction against non-alcoholic fatty liver disease based on network pharmacology and experimental verification[J]. Pharmacology and Clinics of Chinese Materia Medica, 2025, 41(3): 2-9.
[39]	施凯舜, 徐峥, 岳跃兵, 等. 当归芍药散对高脂饮食诱导的非酒精性脂肪肝小鼠模型的影响[J]. 上海中医药杂志, 2021, 55(9): 81-85. SHI K S, XU Z, YUE Y B, et al. Effect of Danggui Shaoyao San on non-alcoholic fattyliver model mice induced by high-fat diet[J]. Shanghai Journal of Traditional Chinese Medicine, 2021, 55(9): 81-85.
[40]	彪雅宁, 张睦清, 韩雪, 等. 当归芍药散对非酒精性脂肪肝大鼠Keap1/Nrf2信号通路的调节作用[J]. 中药药理与临床, 2022, 38(1): 13-18. BIAO Y N, ZHANG M Q, HAN X, et al. Regulatory effect of Danggui Shaoyao San on Keap1/Nrf2 signaling pathway in rats with non-alcoholic fatty liver disease[J]. Pharmacology and Clinics of Chinese Materia Medica, 2022, 38(1): 13-18.
[41]	施凯舜, 徐峥, 陈岩, 等. 基于Dusp9介导的ASK1-JNKp38信号通路探讨当归芍药散对非酒精性脂肪肝模型小鼠的作用机制[J]. 江苏中医药, 2021, 53(8): 74-79. SHI K S, XU Z, CHEN Y, et al. Exploring the mechanism of Danggui Shaoyao San on non-alcoholic fatty liver model mice based on Dusp9-mediated ASK1-JNKp38 signaling pathway[J]. Jiangsu Journal of Traditional Chinese Medicine, 2021, 53(8): 74-79.
[42]	董璐, 曹雪艳, 成路平, 等. 苓桂术甘汤联合多烯磷脂酰胆碱治疗非酒精性脂肪肝病疗效观察[J]. 海南医学, 2022, 33(1): 36-38. DONG L, CAO X Y, CHENG L P, et al. Efficacy observation of Linggui Zhugan Decoction Combined with polyene phosphatidylcholine in the treatment of non-alcoholic fatty liver disease[J]. Hainan Medical Journal, 2021, 33(1): 36-38.
[43]	张傲, 李然, 刘立萍, 等. 基于网络药理学和分子对接技术探讨苓桂术甘汤改善非酒精性脂肪性肝病的潜在作用机制[J]. 中医临床研究, 2024, 16(4): 9-15. ZHANG A, LI R, LIU L P, et al. Exploring the potential mechanism of Linggui Zhugan Decoction in improving non-alcoholic fatty liver disease based on network pharmacology and molecular docking technology[J]. Clinical Journal of Chinese Medicine, 2024, 16(4): 9-15.
[44]	曹慧敏, 孔亮, 隋国媛, 等. 苓桂术甘汤调控自噬对多柔比星抗非酒精性脂肪肝病相关肝细胞癌的增效作用[J]. 中国药房, 2023, 34(19): 2316-2322. CAO H M, KONG L, SUI G Y, et al. Synergistic effect of Linggui Zhugan Decoction regulating autophagy on doxorubicin against non-alcoholic fatty liver disease-related hepatocellular carcinoma[J]. China Pharmacy, 2023, 34(19): 2316-2322.
[45]	宋汶轩, 李爽, 安梦娇, 等. 茵陈公英汤通过IRS/AKT/FoxO1和TLR4/NF-κB信号通路改善非酒精性脂肪肝病[J]. 中药药理与临床, 2025, 41(2): 8-15. SONG W X, LI S, AN M J, et al. Yinchen Gongying Decoction ameliorates NAFLD viaIRS/AKT/FoxO1 and TLR4/NF-B signaling pathways[J]. Pharmacology and Clinics of Chinese Materia Medica, 2025, 41(2): 8-15.
[46]	谭梅傲, 周遵明, 彭冲, 等. 芪葛汤通过调节花生四烯酸代谢防治非酒精性脂肪肝的机制研究[J]. 时珍国医国药, 2024, 35(9): 2112-2116. TAN M A, ZHOU Z M, PENG C, et al. Mechanism study of Qi Ge Decoction in preventingand treating non-alcoholic fatty liver disease by regulating arachidonic acid metabolism[J]. Journal of Lishizhen Traditional Chinese Medicine, 2024, 35(9): 2112-2116.
[47]	黄兰蔚, 王瑞华, 王宇, 等. 补气消脂方调控PI3K/AKT/mTOR通路改善自噬减轻小鼠非酒精性脂肪肝机制研究[J]. 中国医院药学杂志, 2025, 45(3): 241-246. HUANG L W, WANG R H, WANG Y, et al. Mechanism of Buqi Xiaozhi Formula in alleviating non-alcoholic fatty liver in mice by improving autophagy via regulating the PI3K/AKT/mTOR pathway[J]. Chinese Journal of Hospital Pharmacy, 2025, 45(3): 241-246.
[48]	庞智文, 刘玉, 宋囡, 等. 加味涤痰汤对非酒精性脂肪肝病大鼠生物节律相关基因的影响及机制[J]. 中国实验方剂学杂志, 2025, 31(6): 115-124. PANG Z W, LIU Y, SONG N, et al. Modified Ditan Tang regulates biorhythm-related genes in rat model of non-alcoholic fatty liver disease[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2025, 31(6): 115-124.
[49]	张远哲, 黎豫川, 蔡琨, 等. 六味降脂汤对非酒精性脂肪肝大鼠氧化应激及AMPK/ACC/CPT1A通路的影响及作用机制研究[J]. 时珍国医国药, 2024, 35(4): 853-858. ZHANG Y Z, LI Y C, CAI K, et al. Study on the effect and mechanism of Liuwei Jiangzhi Decoction on oxidative stress and AMPK/ACC/CPT1A pathway in rats with non-alcoholic fatty liver disease[J]. Journal of Lishizhen Traditional Chinese Medicine, 2024, 35(4): 853-858.
[50]	XU L, YIN L, QI Y, et al. 3D disorganization and rearrangement of genome provide insights into pathogenesis of NAFLD by integrated Hi-C, Nanopore, and RNA sequencing[J]. Acta Pharm Sin B, 2021, 11(10): 3150-3164. doi: 10.1016/j.apsb.2021.03.022